When ≥5% of tumor cells expressing PD-L1 was defined as a cutoff, patients, treated with pembrolizumab plus lenvatinib as non-first-line therapy, with positive PD-L1 expression had a significantly higher clinical benefit rate (CBR) than patients with negative PD-L1 expression (72.7%, 8/11 vs. 23.8%, 5/21, p=0.021) (20). Here, CD274 is linked to neoplasm.